Cargando…

Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study

Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez-Gaitan, Esteban Alejandro, Garcia-Ortega, Yessica Eleanet, Saldaña-Cruz, Ana Miriam, Contreras-Haro, Betsabe, Gamez-Nava, Jorge Ivan, Perez-Guerrero, Emilio Edsaul, Nava-Valdivia, Cesar Arturo, Gallardo-Moya, Sergio, Martinez-Hernandez, Alejandra, Gonzalez Lopez, Laura, Rios-Gonzalez, Blanca Esthela, Marquez-Pedroza, Jazmin, Mendez-del Villar, Miriam, Esparza-Guerrero, Yussef, Villagomez-Vega, Alejandra, Macias Islas, Miguel Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572793/
https://www.ncbi.nlm.nih.gov/pubmed/37834042
http://dx.doi.org/10.3390/ijms241914594
Descripción
Sumario:Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by genetic factors such as genetic variants. Therefore, our study aimed to investigate the association of the HLA-DRB1*0403 genetic variant and therapeutic response to DMTs in MS. We included 105 patients with MS diagnosis. No evidence of disease activity based on the absence of clinical relapse, disability progression or radiological activity (NEDA-3) was used to classify the therapeutic response. Patients were classified as follows: (a) controls: patients who achieved NEDA-3; (b) cases: patients who did not achieve NEDA-3. DNA was extracted from peripheral blood leukocytes. HLA-DRB1*0403 genetic variant was analyzed by quantitative polymerase chain reaction (qPCR) using TaqMan probes. NEDA-3 was achieved in 86.7% of MS patients treated with DMTs. Genotype frequencies were GG 50.5%, GA 34.3%, and AA 15.2%. No differences were observed in the genetic variant AA between patients who achieved NEDA-3 versus patients who did not achieve NEDA-3 (48.7% vs. 43.1%, p = 0.6). We concluded that in Mexican patients with MS, HLA-DRB1*0403 was not associated with the therapeutic response to DMTs.